Relamorelin

Phase 3Small molecule

AbbVie

Relamorelin is one of 46 small molecule programs targeting Gastroparesis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GastroparesisActive, not recruiting

GastroparesisPhase 3

Active, not recruiting

Competition

Competitive Landscape

61 competitors in Gastroparesis

#DrugCompanyPhaseTrials

Cialis

Eli Lilly

Approved

1 2

Zelnorm

AAlfasigma S.p.A.

Approved

1 3

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

1 4

Haldol

DDePuy Orthopaedics

Approved

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Relistor

Pitocin

Resotran

2 9

Mosapride

SSeoul National University Hospital

Approved

1 10

Nereus

VVanda Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gastroparesis6 trials

Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02

Terminated· AbbVie logo

AbbVie·Phase 3·NCT03426345·311 enrolled

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

Terminated· AbbVie logo

AbbVie·Phase 3·NCT03383146·450 enrolled

Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

Completed· AbbVie logo

AbbVie·Phase 2·NCT02357420·393 enrolled

Show 3 more trials

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

Terminated· AbbVie logo

AbbVie·Phase 3·NCT03420781·467 enrolled

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

Terminated· AbbVie logo

AbbVie·Phase 3·NCT03285308·336 enrolled

Diabetic Gastroparesis Study 05

Terminated· AbbVie logo

AbbVie·Phase 3·NCT03786380·202 enrolled

Function1 trial

Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers

Completed·MMotus Therapeutics, Inc.·Phase 1·NCT02466711·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Relamorelin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Relamorelin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Relamorelin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AbbVie

Relamorelin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gastroparesis6 trials

Function1 trial

References

Drug Info

Quick Facts

Related News